Moleculin Biotech (NASDAQ:MBRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Moleculin Biotech (NASDAQ:MBRX) from a strong sell rating to a sell rating in a research report report published on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Trading Down 0.8%

Shares of MBRX opened at $0.61 on Friday. The company has a market capitalization of $4.31 million, a PE ratio of -0.03 and a beta of 1.84. Moleculin Biotech has a 12 month low of $0.16 and a 12 month high of $17.23. The stock’s 50-day moving average price is $1.99 and its two-hundred day moving average price is $2.45.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.40) EPS for the quarter, beating analysts’ consensus estimates of ($1.55) by $0.15. Equities research analysts predict that Moleculin Biotech will post -3.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.